Delayed Development of Linezolid Resistance in Staphylococcus aureus following Exposure to Low Levels of Antimicrobial Agents

Antimicrobial Agents and Chemotherapy
2008.0

Abstract

The development of resistance to linezolid (LZD) in gram-positive bacteria depends on the mutation of a single 23S rRNA gene, followed by homologous recombination and gene conversion of the other alleles. We sought to inhibit this process in Staphylococcus aureus using a range of antibacterial agents, including some that suppress recombination. A model for the rapid selection of LZD resistance was developed which allowed the selection of LZD-resistant mutants with G2576T mutations in all five copies of the 23S rRNA gene following only 5 days of subculture. The emergence of LZD-resistant isolates was delayed by exposing cultures to low concentrations of various classes of antibiotics. All antibiotic classes were effective in delaying the selection of LZD-resistant mutants and, with the exception of fusidic acid (FUS) and rifampin (RIF), prolonged the selection window from 5 to approximately 15 days. Inhibitors of DNA processing were no more effective than any other class of antibiotics at suppressing resistance development. However, the unrelated antimicrobials FUS and RIF were particularly effective at preventing the emergence of LZD resistance, prolonging the selection window from 5 to 25 days. The enhanced suppressive effect of FUS and RIF on the development of LZD resistance was lost in a recA-deficient host, suggesting that these drugs affect recA-dependent recombination. Furthermore, FUS and RIF were shown to be effective inhibitors of homologous recombination of a plasmid into the staphylococcal chromosome. We suggest that RIF or FUS in combination with LZD may have a role in preventing the emergence of LZD resistance.

Knowledge Graph

Similar Paper

Delayed Development of Linezolid Resistance in Staphylococcus aureus following Exposure to Low Levels of Antimicrobial Agents
Antimicrobial Agents and Chemotherapy 2008.0
Elevated Linezolid Resistance in Clinical cfr -Positive Staphylococcus aureus Isolates Is Associated with Co-Occurring Mutations in Ribosomal Protein L3
Antimicrobial Agents and Chemotherapy 2010.0
Linezolid Resistance in Staphylococcus aureus : Gene Dosage Effect, Stability, Fitness Costs, and Cross-Resistances
Antimicrobial Agents and Chemotherapy 2008.0
Linezolid and Tiamulin Cross-Resistance in Staphylococcus aureus Mediated by Point Mutations in the Peptidyl Transferase Center
Antimicrobial Agents and Chemotherapy 2008.0
Activity of Linezolid in anIn VitroPharmacokinetic-Pharmacodynamic Model Using Different Dosages andStaphylococcus aureusandEnterococcus faecalisStrains with and without a Hypermutator Phenotype
Antimicrobial Agents and Chemotherapy 2010.0
Influence of Recombination on Development of Mutational Resistance to Linezolid in Enterococcus faecalis JH2-2
Antimicrobial Agents and Chemotherapy 2009.0
First Report of cfr -Mediated Resistance to Linezolid in Human Staphylococcal Clinical Isolates Recovered in the United States
Antimicrobial Agents and Chemotherapy 2008.0
Mutations in 23S rRNA at the Peptidyl Transferase Center and Their Relationship to Linezolid Binding and Cross-Resistance
Antimicrobial Agents and Chemotherapy 2010.0
Mutations in Ribosomal Protein L3 Are Associated with Oxazolidinone Resistance in Staphylococci of Clinical Origin
Antimicrobial Agents and Chemotherapy 2009.0
Resistance Selection Studies Comparing the Activity of Razupenem (PTZ601) to Vancomycin and Linezolid against Eight Methicillin-Resistant and Two Methicillin-Susceptible Staphylococcus aureus Strains
Antimicrobial Agents and Chemotherapy 2009.0